Pfizer Inc. (PFE)
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Pfizer (PFE) closed at $26.75, marking a -0.41% move from the previous day.
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis suggests stock ought to be valued ~$50, but this depends on the business becoming significantly derisked by new product launches, operational efficiencies, & debt paydown. Pfizer management say its key focus areas include improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation to enhance shareholder value in 2025.
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.
Here's How to Play Pfizer Stock Before Q4 Earnings Release
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
On Saturday, Pfizer Inc. PFE revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT, the U.S. Department of Justice said on Friday.
Here's Why Pfizer (PFE) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can This Beaten-Down Stock Bounce Back in 2025?
In 2022, pharmaceutical giant Pfizer (PFE -2.37%) became the first healthcare company to generate $100 billion in annual sales. But since that notable achievement, its financial results have fallen off a cliff, as has its stock price.
Is Pfizer Stock a Buy?
Pharmaceutical giant Pfizer (PFE 1.29%) is trading near its lowest price in over a decade.
